![Oncolytic Virus Immunotherapy Market (Type: Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Others; Route of Administration: Intratumoral and Intravenous; and Application: Melanoma, Non-small Cell Lung Cancer [NSCLC], Pancreatic Cancer, Breast Cancer, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030「世界の腫瘍溶解性ウイルス免疫治療市場2020年-2030年：種類別（単純ヘルペスウイルス、ワクシニアウイルス、アデノウイルス、レオウイルス、その他）、投与経路別、用途別」（市場規模、市場予測）調査レポートです。](https://www.marketresearchcenter.net/images/market-size-forecast-data-27.GIF) | • レポートコード：MRC2102A024 • 出版社/出版日：Transparency Market Research / 2020年10月1日 • レポート形態：英文、PDF、182ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User（1名様閲覧） | ￥822,890 (USD5,795) | ▷ お問い合わせ |
| Site Licence（同一拠点内共有可） | ￥1,248,890 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide Licence（複数拠点内共有可） | ￥1,674,890 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本市場調査レポートでは、世界の腫瘍溶解性ウイルス免疫治療市場について調査・分析し、序論、仮定/調査手法、エグゼクティブサマリー、市場概要、キーインサイト、種類別（単純ヘルペスウイルス、ワクシニアウイルス、アデノウイルス、レオウイルス、その他）分析、投与経路別分析、用途別分析、地域別（北米、ヨーロッパ、アジア太平洋、その他）分析、競争状況を掲載しています。 ・序論 ・仮定/調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の腫瘍溶解性ウイルス免疫治療市場規模：種類別（単純ヘルペスウイルス、ワクシニアウイルス、アデノウイルス、レオウイルス、その他） ・世界の腫瘍溶解性ウイルス免疫治療市場規模：投与経路別 ・世界の腫瘍溶解性ウイルス免疫治療市場規模：用途別 ・世界の腫瘍溶解性ウイルス免疫治療市場規模：地域別（北米、ヨーロッパ、アジア太平洋、その他） ・競争状況 |
Oncolytic Virus Immunotherapy Market – Scope of the Report
TMR’s report on the global oncolytic virus immunotherapy market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global oncolytic virus immunotherapy market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global oncolytic virus immunotherapy market during the forecast period.
The report has been prepared after primary and secondary researches. Primary research involves bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global oncolytic virus immunotherapy market.
Secondary research also includes Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global oncolytic virus immunotherapy market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global oncolytic virus immunotherapy market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global oncolytic virus immunotherapy market.
The report delves into the competition landscape of the global oncolytic virus immunotherapy market. Key players operating in the global oncolytic virus immunotherapy market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global oncolytic virus immunotherapy market that have been profiled in this report.
Key Questions Answered in Oncolytic Virus Immunotherapy Market Report
What is the scope of growth for product companies in the global oncolytic virus immunotherapy market?
What will be the Y-o-Y growth of the global oncolytic virus immunotherapy market between 2020 and 2030?
What is the influence of changing trends in technologies on the global oncolytic virus immunotherapy market?
Will North America continue to be the most profitable market for oncolytic virus immunotherapy?
Which factors are anticipated to hamper the global oncolytic virus immunotherapy market during the forecast period?
Which are the leading companies in the global oncolytic virus immunotherapy market?
Research Methodology
A unique methodology has been utilized by TMR to conduct comprehensive research on the growth of the global oncolytic virus immunotherapy market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary research sources referred to by analysts during the production of the global oncolytic virus immunotherapy market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the oncolytic virus immunotherapy market as primary methods.
These primary research respondents have provided exclusive information during interviews, which serves as a validation from the oncolytic virus immunotherapy market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global oncolytic virus immunotherapy market with accuracy. The study also uses the top-down approach to assess the revenue of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global oncolytic virus immunotherapy more reliably and accurately
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Oncolytic Virus Immunotherapy Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, 2018–2030
5. Key Insights
5.1. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.2. Pipeline Analysis
5.3. Key Industry Developments
5.4. Features of oncolytic viruses
6. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030
6.3.1. Herpes Simplex Virus
6.3.2. Vaccinia Virus
6.3.3. Adenovirus
6.3.4. Reovirus
6.3.5. Others
6.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type
7. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030
7.3.1. Intratumoral
7.3.2. Intravenous
7.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration
8. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030
8.3.1. Melanoma
8.3.2. Non-small Cell Lung Cancer (NSCLC)
8.3.3. Pancreatic Cancer
8.3.4. Breast Cancer
8.3.5. Others
8.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application
9. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Rest of World
9.3. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Region
10. North America Oncolytic Virus Immunotherapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030
10.2.1. Herpes Simplex Virus
10.2.2. Vaccinia Virus
10.2.3. Adenovirus
10.2.4. Reovirus
10.2.5. Others
10.3. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030
10.3.1. Intratumoral
10.3.2. Intravenous
10.4. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030
10.4.1. Melanoma
10.4.2. Non-small Cell Lung Cancer (NSCLC)
10.4.3. Pancreatic Cancer
10.4.4. Breast Cancer
10.4.5. Others
10.5. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Country, 2018–2030
10.5.1. U.S.
10.5.2. Canada
10.6. North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Route of Administration
10.6.3. By Application
10.6.4. By Country
11. Europe Oncolytic Virus Immunotherapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030
11.2.1. Herpes Simplex Virus
11.2.2. Vaccinia Virus
11.2.3. Adenovirus
11.2.4. Reovirus
11.2.5. Others
11.3. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030
11.3.1. Intratumoral
11.3.2. Intravenous
11.4. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030
11.4.1. Melanoma
11.4.2. Non-small Cell Lung Cancer (NSCLC)
11.4.3. Pancreatic Cancer
11.4.4. Breast Cancer
11.4.5. Others
11.5. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Route of Administration
11.6.3. By Application
11.6.4. By Country/Sub-region
12. Asia Pacific Oncolytic Virus Immunotherapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030
12.2.1. Herpes Simplex Virus
12.2.2. Vaccinia Virus
12.2.3. Adenovirus
12.2.4. Reovirus
12.2.5. Others
12.3. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030
12.3.1. Intratumoral
12.3.2. Intravenous
12.4. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030
12.4.1. Melanoma
12.4.2. Non-small Cell Lung Cancer (NSCLC)
12.4.3. Pancreatic Cancer
12.4.4. Breast Cancer
12.4.5. Others
12.5. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Route of Administration
12.6.3. By Application
12.6.4. By Country/Sub-region
13. Rest of World Oncolytic Virus Immunotherapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030
13.2.1. Herpes Simplex Virus
13.2.2. Vaccinia Virus
13.2.3. Adenovirus
13.2.4. Reovirus
13.2.5. Others
13.3. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030
13.3.1. Intratumoral
13.3.2. Intravenous
13.4. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030
13.4.1. Melanoma
13.4.2. Non-small Cell Lung Cancer (NSCLC)
13.4.3. Pancreatic Cancer
13.4.4. Breast Cancer
13.4.5. Others
13.5. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Route of Administration
13.6.3. By Application
13.6.4. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis/Ranking, by Company, 2019
14.3. Company Profiles
14.3.1. Amgen Inc.
14.3.1.1. Company Overview
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Merck & Co., Inc. (Viralytics Limited)
14.3.2.1. Company Overview
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Shanghai Sunway Biotech Co., Ltd
14.3.3.1. Company Overview
14.3.3.2. Growth Strategies
14.3.3.3. SWOT Analysis
14.3.4. TILT Biotherapeutics
14.3.4.1. Company Overview
14.3.4.2. Growth Strategies
14.3.4.3. SWOT Analysis
14.3.5. Oncorus, Inc.
14.3.5.1. Company Overview
14.3.5.2. Growth Strategies
14.3.5.3. SWOT Analysis
14.3.6. Replimune Group, Inc.
14.3.6.1. Company Overview
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Oncolys BioPharma, Inc.
14.3.7.1. Company Overview
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Sorrento Therapeutics, Inc.
14.3.8.1. Company Overview
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Oncolytics Biotech, Inc.
14.3.9.1. Company Overview
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. SillaJen, Inc.
14.3.10.1. Company Overview
14.3.10.2. Growth Strategies
14.3.10.3. SWOT Analysis
List of TableTable 01: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 02: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 03: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 04: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 05: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country, 2018–2030
Table 06: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030
Table 07: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 08: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030
Table 09: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 10: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030
Table 11: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 12: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030
Table 13: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030
Table 15: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 16: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030
Table 17: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030
Table 18: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 19: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030